Brief: Hansa Biopharma AB Says Treatment Idefirix Granted ASMR 3 Rating By French Transparency Commission
20/04/2022 17:04
April 20 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA AB - TREATMENT IDEFIRIX GRANTED ASMR 3
RATING BY
TRANSPARENCY COMMISSION OF FRENCH NATIONAL AUTHORITY FOR HEALTH
Source text for Eikon: ID:nWkr1YQTTC
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS